首页> 外文期刊>Schweizer Archiv fur Tierheilkunde >Efficacy of the combination of gluco-corticoids, mycophenolate-mofetil and human immunoglobulin for the therapy of immune mediated haemolytic anaemia in dogs
【24h】

Efficacy of the combination of gluco-corticoids, mycophenolate-mofetil and human immunoglobulin for the therapy of immune mediated haemolytic anaemia in dogs

机译:葡萄球菌,霉酚酸酯 - MoFetil和人免疫球蛋白组合治疗免疫介导的血液溶解性血液血栓磷的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Idiopathic immune-mediated haemolytic anaemia (IMHA) is one of the most common immune-mediated diseases in dogs with a high mortality rate. In this retrospective study, we examined the effect of mycophenolate-mofetil (MMF) and human intravenous immunoglobulin (hIVIG) in combination with glucocorticoids on canine IMHA patients. Six dogs were treated with prednisolone and MMF (hIVIG-) and in 15 patients hIVIG was added (hIVIG+). There was no significant difference between the groups regarding age, weight, number of blood transfusions or hematocrit on the day of diagnosis. The hIVIG+ group showed a significantly faster recovery of the hematocrit, but this difference was only short-lived. The survival in the first year was similar in both groups and was with 71.5% somewhat higher than in other published studies. The addition of MMF to prednisolone for the treatment of dogs with acute IMHA was well tolerated and seemed to positively affect the course of the disease. Randomized studies are necessary to confirm this observation. Human immunoglobulin had only minimal clinical advantages and no effect on mortality.
机译:特发性免疫介导的溶血性贫血(IMHA)是具有高死亡率的狗中最常见的免疫介导的疾病之一。在这项回顾性研究中,我们研究了霉酚酸酯 - MoFetil(MMF)和人静脉内免疫球蛋白(HIVIG)与甘氨酸IMHA患者的糖皮质激素的影响。用泼尼松龙和MMF(HIVIG-)和MMF(HIVIG-)和MMF(HIVIG +)治疗六只狗(HIVIG +)。关于年龄,重量,输血或血液系列的血液分子的群体之间没有显着差异。 HIVIG +组显示出血细胞比容的速度明显更快,但这种差异仅仅是短暂的。第一年的生存在这两组中相似,并且比其他出版的研究略高了71.5%。向泼尼松龙添加MMF用于治疗急性IMHA的狗的耐受性,似乎积极影响疾病的过程。随机研究是确认此观察的必要条件。人免疫球蛋白只有最小的临床优势,对死亡率没有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号